Antioxidant drug shows promise for kids with NF1
NCT ID NCT04481048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether N-acetylcysteine (NAC), an antioxidant drug, can improve motor skills and learning in children with neurofibromatosis type 1 (NF1). Twenty-five children aged 8 to 16 took NAC or a placebo for 8 weeks. The goal was to see if NAC is safe and helps with movement and attention problems common in NF1.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- N-acetylcysteine (NAC)
- What this could lead to
- If it works, this could point toward a treatment for motor and learning problems in children with NF1.
- What could go wrong
- This is a small, early-phase trial with only 25 participants. Results may not apply to all children with NF1, and the treatment may not show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- New drug combo shows promise for rare nerve tumors
- Can a simple walk test spot motor trouble in kids with NF1?
- New drug aims to help kids with rare genetic short stature grow taller